leronlimab

Home
Ligands
leronlimab

GtoPdb Ligand ID: 10752

Synonyms: PRO 140 | PRO-140 | PRO140 | Vyrologix®

Comment: Leronlimab (PRO140) is a humanized anti-CCR5 (C-C motif chemokine receptor 5) monoclonal antibody [5-6]. It was originally developed by CytoDyn as a novel strategy to manage CCR5-tropic HIV infection [4].

SARS-CoV-2 and COVID-19: Leronlimab has been administered to a number of patients with severe COVID-19, to determine its potential to reduce cytokine storm caused by this disease.

No information available.

No information available.

Summary of Clinical Use
In addition to HIV, leronlimab has been re-positioned for some metastatic solid tumours, particularly triple negative breast cancer, and Graft-versus-host disease [1]. with the advent of COVID-19, leronlimab is being given to some patients with severe disease, under compassionate use or an emergency IND, and concurrent with the initiation of formal clinical trials. Although not published yet, preliminary evidence indicates that in COVID-19 patients leronlimab reduces levels of cytokine storm cytokines IL-6, and TNFα, provides immunological benefit, and promotes signifiant recovery within a few days following treatment [2-3].

Summary of Clinical Use

In addition to HIV, leronlimab has been re-positioned for some metastatic solid tumours, particularly triple negative breast cancer, and Graft-versus-host disease [1]. with the advent of COVID-19, leronlimab is being given to some patients with severe disease, under compassionate use or an emergency IND, and concurrent with the initiation of formal clinical trials. Although not published yet, preliminary evidence indicates that in COVID-19 patients leronlimab reduces levels of cytokine storm cytokines IL-6, and TNFα, provides immunological benefit, and promotes signifiant recovery within a few days following treatment [2-3].

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT02859961	Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection	Phase 2/Phase 3 Interventional	CytoDyn, Inc.
NCT02737306	Study of PRO 140 for Prophylaxis of Acute GVHD in Patients Undergoing RIC Allogenic Stem-Cell Transplantaton	Phase 2 Interventional	CytoDyn, Inc.
NCT03838367	Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC	Phase 1/Phase 2 Interventional	CytoDyn, Inc.
NCT04343651	Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19	Phase 2 Interventional	CytoDyn, Inc.
NCT04347239	Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)	Phase 2 Interventional	CytoDyn, Inc.